https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42351 Wed 30 Aug 2023 15:15:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9806 Wed 11 Apr 2018 12:15:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20127 Tue 24 Aug 2021 14:32:29 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:19941 Tue 18 Aug 2015 11:14:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33182 Thu 13 Jan 2022 10:31:51 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37732 p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p <0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p <0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p <0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). Interpretation: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.]]> Mon 29 Mar 2021 13:09:59 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46204 Mon 14 Nov 2022 11:30:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54765 Mon 11 Mar 2024 15:01:55 AEDT ]]>